The recommended starting dose of INVOKANA® is 100 mg once daily. In patients tolerating the starting dose who have an eGFR ≥60 mL/min/1.73 m2 and require additional glycemic control, the dose can be increased to 300 mg once daily.1

*Access statuses sourced from MMIT. Data on file. Janssen Pharmaceuticals, Inc. Data as of January 30, 2018.

As demonstrated across clinical trials such as those of monotherapy vs placebo, triple combination therapy with metformin and a sulfonylurea vs Januvia® (sitagliptin) 100 mg, and dual combination therapy with metformin vs glimepiride (with a mean daily dose of 5.6 mg; glimepiride titration up to 6 mg or 8 mg was allowed throughout the study).

SGLT2=sodium-glucose co-transporter 2. 

Indicated trademarks are registered trademarks of their respective owners.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Farxiga® [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP. 3. Jardiance® [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 4. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. 5. Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.